This RARE edition features Ulf Staginnus, a seasoned expert in Market Access and Pricing, who unpacks what it really takes for biotechs to succeed in Europe. Drawing on nearly 30 years of experience, Ulf discusses the future of HTA, payer negotiation strategies, and the shifting policy environment shaping access to orphan and precision medicines.
